Articles related to HEALTH OUTCOMES

Promising Discovery: Existing Drugs Could Be Repurposed for First Treatment of Dementia-Linked Strokes Clinical trials reveal the potential of two commonly used cardiac drugs, isosorbide mononitrate and cilostazol, to serve as novel treatment options for lacunar strokes, a leading cause of dementia. Key Points: “Now we understand more about what is triggering these small vessel strokes to attack the brain, we’ve been able to focus our efforts on treatments that can put a halt to this damage…as these drugs are already widely available for other circulatory disorders, and inexpensive, it shouldn’t take too long to move our findings from research into everyday clinical practice.” Professor Joanna Wardlaw of the University of Edinburgh and UK Dementia Research Institute

Similarities in Quality and Cost of Care: Allopathic vs. Osteopathic Physicians As the medical field continues to evolve and diversify, it is imperative to understand the impact of physician education on patient outcomes and healthcare costs. This comprehensive observational study offers an insightful comparison between allopathic and osteopathic physicians in the context of hospitalized Medicare patients, revealing striking similarities in both the quality and cost of care provided.

Dive into the potential of senolytics in combating age-related diseases, revealing how these compounds might unlock a healthier, longer life. Although senescent cells play crucial roles in early life, their persistence in later years can link to numerous age-related diseases. The potential of senolytics, such as dasatinib and quercetin (D&Q), is being explored in clearing out these harmful cells and combating age-related diseases like cancer, diabetes, and osteoporosis. To illustrate, researchers applied D&Q as senolytics in patients with idiopathic pulmonary fibrosis (IPF) and diabetic kidney disease. Findings revealed that patients showed improvements in physical function, with benefits including enhanced gait speed and increased walking distance. Similarly, the treatment significantly reduced cellular senescence in another study involving patients with diabetic kidney disease. However, caution is advised. Experts insist on the need for additional long-term studies and human clinical trials to confirm the safety of these senolytics. The majority of global morbidity, mortality, and health costs stem from chronic illnesses. Age, as indicated by JAMA, is a significant predictive factor for most of these diseases. Therefore, research aiming to “turn back the clock” and mitigate the effects of aging is well underway. Among the promising strategies is the removal of senescent cells, […]

The authors evaluated the treatment approaches and outcomes of 110 patients with primary plasma cell leukemia (pPCL) in this retrospective study . Higher complete response rates were associated with treatment with bortezomib, lenalidomide, and dexamethasone (VRd) or daratumumab-based quadruplets (DBQ) and autologous stem-cell transplantation. Patients who received VRd/DBQ had better outcomes than those who received other bortezomib-based combinations or standard chemotherapy.

According to the findings of this study, patients with rectal cancer who were monitored using a watch-and-wait approach had a good quality of life, with some patients reporting bowel and sexual dysfunction. When patients needed surgery, their quality of life and functional outcome deteriorated. These findings will be useful in daily practice to advise patients on what to expect from a wait-and-see approach.

Lumateperone 42 mg/d is effective in the treatment of schizophrenia and has no clinically significant effects on body weight, metabolic variables, motor function, the ECG QT interval, or prolactin levels, with a likelihood to be helped or harmed (LHH) much greater than 1 when comparing therapeutic response to these tolerability/safety outcomes. When comparing therapeutic response versus a somnolence/sedation AE, lumateperone appears to be associated with somnolence/sedation, and LHH approaches 1. In indirect comparisons with other antipsychotics, this somnolence/sedation AE profile is not dissimilar; however, the absence of weight gain, glucose/lipid abnormalities, and akathisia, as well as the absence of prolactin elevations, distinguishes lumateperone.